Fuller & Thaler Asset Management’s PTC Therapeutics PTCT Stock Holding History

Fuller & Thaler Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$94.4M	Buy	+1,156,819	New	+$83.5M	0.26%	135

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management's PTCT Position: Q2 2026 in Review

Fuller & Thaler Asset Management opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 1,156,819 shares worth $94.4M. The stake represents 0.26% of the portfolio and ranks #135 among its holdings.

228 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Fuller & Thaler Asset Management held 1,156,819 shares of PTC Therapeutics worth $94.4M as of Q2 2026.
PTC Therapeutics was a new Fuller & Thaler Asset Management position in Q2 2026.
PTC Therapeutics made up 0.26% of Fuller & Thaler Asset Management's portfolio in Q2 2026, its #135 holding.
228 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.